Two-Punch therapy takes on tough leukemia
NCT ID NCT07342244
First seen Jan 18, 2026 · Last updated May 19, 2026 · Updated 20 times
Summary
This study tests a two-step treatment for people with a tough type of leukemia (AML) that has come back or not responded to standard chemo. First, patients receive a special immune cell therapy (CLL1 CAR-T) to target cancer cells, followed by a stem cell transplant to rebuild a healthy blood system. The goal is to see if this combination is safe and helps patients live longer. The study plans to enroll 18 adults aged 18 to 75.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AML are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology
Wuhan, Hubei, 448000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.